Peringatan Keamanan

There is no information available regarding the LD50 and overdose of lecanemab.

Lecanemab

DB14580

biotech approved investigational

Deskripsi

Lecanemab is a recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta (A?), which are implicated in the pathophysiology of Alzheimer’s disease.L44537 Lecanemab works to reduce A? plaques and prevent A? deposition in the brain A253947,A253952 with high selectivity to A? protofibrils.A253947,A253957 In clinical trials, it significantly reduced brain A? plaques compared to placebo.A253962,L44547

On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.L44547 It was granted full FDA approval on July 6, 2023.L47226

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The terminal half-life is 5 to 7 days.[L44537]
Volume Distribusi The mean value (95% CI) for the central volume of distribution at steady-state is 3.22 (3.15-3.28) L.[L44537]
Klirens (Clearance) The clearance of lecanemab (95% CI) is 0.434 (0.420-0.451) L/day.[L44537]

Absorpsi

Steady-state concentrations of lecanemab were reached after six weeks when 10 mg/kg of lecanemab was administered every two weeks. Systemic accumulation was 1.4-fold. The peak concentration (Cmax) and area under the plasma concentration versus time curve (AUC) of lecanemab increased dose proportionally following a single dose ranging from 0.3 to 15 mg/kg.L44537

Metabolisme

Lecanemab is degraded by proteolytic enzymes in the same manner as endogenous IgGs.L44537

Rute Eliminasi

There is no information available.

Interaksi Obat

373 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Lecanemab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Lecanemab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Lecanemab.
Estrone Estrone may increase the thrombogenic activities of Lecanemab.
Estradiol Estradiol may increase the thrombogenic activities of Lecanemab.
Dienestrol Dienestrol may increase the thrombogenic activities of Lecanemab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Lecanemab.
Mestranol Mestranol may increase the thrombogenic activities of Lecanemab.
Estriol Estriol may increase the thrombogenic activities of Lecanemab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Lecanemab.
Quinestrol Quinestrol may increase the thrombogenic activities of Lecanemab.
Hexestrol Hexestrol may increase the thrombogenic activities of Lecanemab.
Tibolone Tibolone may increase the thrombogenic activities of Lecanemab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Lecanemab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lecanemab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Lecanemab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Lecanemab.
Zeranol Zeranol may increase the thrombogenic activities of Lecanemab.
Equol Equol may increase the thrombogenic activities of Lecanemab.
Promestriene Promestriene may increase the thrombogenic activities of Lecanemab.
Methallenestril Methallenestril may increase the thrombogenic activities of Lecanemab.
Epimestrol Epimestrol may increase the thrombogenic activities of Lecanemab.
Moxestrol Moxestrol may increase the thrombogenic activities of Lecanemab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Lecanemab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Lecanemab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Lecanemab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Lecanemab.
Biochanin A Biochanin A may increase the thrombogenic activities of Lecanemab.
Formononetin Formononetin may increase the thrombogenic activities of Lecanemab.
Estetrol Estetrol may increase the thrombogenic activities of Lecanemab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Lecanemab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lecanemab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Lecanemab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Lecanemab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Lecanemab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lecanemab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lecanemab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Lecanemab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lecanemab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Lecanemab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Lecanemab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Lecanemab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lecanemab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lecanemab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Lecanemab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lecanemab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lecanemab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Lecanemab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lecanemab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Lecanemab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Lecanemab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Lecanemab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lecanemab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lecanemab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Lecanemab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Lecanemab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Lecanemab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Lecanemab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Lecanemab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Lecanemab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Lecanemab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Lecanemab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Lecanemab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Lecanemab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Lecanemab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Lecanemab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Lecanemab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Lecanemab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Lecanemab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Lecanemab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Lecanemab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Lecanemab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Lecanemab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Lecanemab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Lecanemab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Lecanemab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Lecanemab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Lecanemab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Lecanemab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Lecanemab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Lecanemab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Lecanemab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Lecanemab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Lecanemab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Lecanemab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Lecanemab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Lecanemab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lecanemab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Lecanemab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Lecanemab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Lecanemab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Lecanemab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Lecanemab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Lecanemab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Lecanemab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Lecanemab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Lecanemab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Lecanemab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Lecanemab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Lecanemab.

Target Protein

Amyloid-beta precursor protein APP

Referensi & Sumber

Artikel (PubMed)
  • PMID: 27048170
    Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, Basun H, Lannfelt L: Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Abeta antibody. Alzheimers Res Ther. 2016 Apr 6;8(1):14. doi: 10.1186/s13195-016-0181-2.
  • PMID: 35493943
    Shi M, Chu F, Zhu F, Zhu J: Impact of Anti-amyloid-beta Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab. Front Aging Neurosci. 2022 Apr 12;14:870517. doi: 10.3389/fnagi.2022.870517. eCollection 2022.
  • PMID: 35516416
    Cummings J, Lee G, Nahed P, Kambar MEZN, Zhong K, Fonseca J, Taghva K: Alzheimer's disease drug development pipeline: 2022. Alzheimers Dement (N Y). 2022 May 4;8(1):e12295. doi: 10.1002/trc2.12295. eCollection 2022.
  • PMID: 33865446
    Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, Cummings JL: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8.
  • PMID: 35300725
    Song C, Shi J, Zhang P, Zhang Y, Xu J, Zhao L, Zhang R, Wang H, Chen H: Immunotherapy for Alzheimer's disease: targeting beta-amyloid and beyond. Transl Neurodegener. 2022 Mar 18;11(1):18. doi: 10.1186/s40035-022-00292-3.
  • PMID: 20061647
    Murphy MP, LeVine H 3rd: Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis. 2010;19(1):311-23. doi: 10.3233/JAD-2010-1221.

Contoh Produk & Brand

Produk: 2 • International brands: 0
Produk
  • Leqembi
    Injection, solution • 100 mg/1mL • Intravenous • US • Approved
  • Leqembi
    Injection, solution • 100 mg/1mL • Intravenous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul